Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence

Mottet, 2021 Rauscher, 2018, Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy, Eur Urol, 73, 656, 10.1016/j.eururo.2018.01.006 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Maurer, 2019, 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer, Eur Urol, 75, 659, 10.1016/j.eururo.2018.03.013 Horn, 2019, Eur Urol, 76, 517, 10.1016/j.eururo.2019.03.045 Alix-Panabières, 2021, Liquid biopsy: from discovery to clinical application, Cancer Discov, 11, 858, 10.1158/2159-8290.CD-20-1311 Pantel, 2019, Circulating tumor cells in prostate cancer: from discovery to clinical utility, Clin Chem, 65, 87, 10.1373/clinchem.2018.287102 de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin Cancer Res, 14, 6302, 10.1158/1078-0432.CCR-08-0872 Fossati, 2019, Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis, Eur Urol, 75, 176, 10.1016/j.eururo.2018.09.009 Bravi, 2020, Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought, Eur Urol, 78, 661, 10.1016/j.eururo.2020.06.043 Kirby, 2012, Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device, PLoS One, 7, e35976, 10.1371/journal.pone.0035976 Salami, 2019, Circulating tumor cells as a predictor of treatment response in clinically localized prostate cancer, JCO Precis Oncol, 3